Medical Marketing Int'l Group PLC
20 February 2004


FOR IMMEDIATE RELEASE 20 FEBRUARY 2004


MMI TO BE GRANTED

US PATENT FOR ANTI CANCER THERAPY


Medical Marketing International Group plc ('MMI') the Cambridge, UK-based
technology management company focussed on the bio-therapeutic sector (LSE : MMG)
announces that it has been formally notified by the US Patent Office that the
patent for its ruthenium anti-cancer therapy, being developed by MMI's
wholly-owned cancer therapy subsidiary Oncosense, will be granted.

MMI announced on 28th October 2003 that it had received notification by the
European Patent Office that the ruthenium patent would be granted in the
European territories.

On 18th September 2003 MMI announced that the Oncosense ruthenium compounds had
the potential to be a whole new class of cancer therapy showing potency at least
as good as the market-leading therapies carboplatin and cisplatin and with the
potential for reduced toxicity, a novel mechanism of action and non-cross
resistance. Additionally data showed that the ruthenium compounds each have
their own spectrum of activity, with individual compounds showing differential
activity against individual cell lines including non-small cell lung cancer,
breast cancer and melanoma.

Mark Burton, Technology Manager at MMI, commenting on today's announcement said:
'We are delighted to have received notification that the ruthenium patent will
grant in the world's biggest cancer therapy market. When added to the European
patent notification this means that we will have protection in two of the
world's largest markets. This news coupled with our technical progress with
ruthenium considerably strengthens our commercial position in the global cancer
therapy market which is worth some $20bn'.


For further information, please contact:

David Best - Executive Chairman
MMI Group Tel: +44 (0)1223 477677

www.mmigroup.co.uk

Lisa Baderoon
Buchanan Communications Tel: +44 (0)20 7466 5000
lisab@buchanan.uk.com


This information is provided by RNS
The company news service from the London Stock Exchange

Mike Walters tipped these last night....under Best Bet......could be worth 100p or more if all goes according to plan..

Thanks Mitzy. I saw the tip. Let it run to 100p and onwards

Two main Directors selling shares--is this a bad sign?

THey sold to the Prudential and M & G securities ..a good sign when institutions want a piece of the action.

Big institutions are coming in.

Some large buying this past week could it be that Prudential are buying more...

It is on the uptrend lately. Is there any news?

Nothing as yet although the institutions are picking them up so there is something happening behind the scenes..

I am a long term holder of mmg since its day's as Bioscience innovation on ofex. Have topped up occasionaly along the way (unfortunately not at 2p)

I would like to hear the views of any chartists on this stock. There seems to be a fairly stronger lower resistance line looking at the one year chart.

Not a chartist myself rob but the chart trendline is still intact so the price could hit a high of 70p..

i have been told that there is news due inthis stock in the next 10 days, i have not followed this one. can someone update on any expected news

Dr Best is back from his holiday and the gossip is he will announce some news on their anti-cancer drug within the the next few days...up 10% today on anticipation of the news.

Thanks. my broker said it is from a good source and is expected inthe next 10 days

european patenet announced

The outlook of ruthenium compounds is outstanding. Buy MMI at 76p.

Another big rise on no new news.. whats happening..?